Collaboration in the Pharmaceutical Industry

Head Trauma and Concussions in Film and Television Stunt Performers

“…The recruitment emails we sent encouraged all ACTRA stunt performers to participate regardless of their head impact history, but obviously with the constraints previously mentioned, it was not possible to compel an ideal participation sample. If ascertainment bias was present, it may have been manifest in the differences between our results and those of Quirke 17 …”

“…Stunt performers’ reporting rates and what factors influence their decisions about reporting concussions are unknown apart from insights offered by Quirke 17 in a 2012 trade whitepaper. Based on worker’s compensation claims in British Columbia, he suggested that head injuries that occurred in stunt performers were severely underreported and that the usual reason for this was performers’ lack of understanding about the severity of the injury.…”

Why the MRC therapeutic trials committee did not introduce controlled clinical trials

“…Given the lack of progress by in-house chemists at NIMR and universities, and the willingness of a leading pharmaceutical company to engage with the Chemotherapy Committee, the time appeared ripe for more sustained engagement between the MRC and the British pharmaceutical industry, thanks to the network of trusted connections built up by Dale, who had successfully moved from university to industry and back again. 25 The immediate events which led to the creation of the TTC began towards the end of the 1920s, when the MRC entered into discussion with the Association of British Chemical Manufacturers (ABCM) to resolve 'the problem of securing trustworthy clinical trials of products produced by manufacturers'. The MRC Annual Report for 1930-1931 sets out the case for closer cooperation between the MRC and the pharmaceutical industry:…”

“…Significant increases in the efficiency of the production of insulin were made at the NIMR during the period in which the MRC held the patent. 25 Following the evident success of cooperation between academia and industry in Germany in the production of Salvarsan, 26 funds were made available to support cooperation between a university and industry to study the bactericidal activity of several compounds. 20 The MRC also supported what would now be called translational research, based on a network of clinical research centres associated with the NIMR.…”

“…Given the lack of progress by in-house chemists at NIMR and universities, and the willingness of a leading pharmaceutical company to engage with the Chemotherapy Committee, the time appeared ripe for more sustained engagement between the MRC and the British pharmaceutical industry, thanks to the network of trusted connections built up by Dale, who had successfully moved from university to industry and back again. 25…”